» Articles » PMID: 25567105

Clostridium Difficile Infection: Risk Factors, Diagnosis and Management

Overview
Specialty Gastroenterology
Date 2015 Jan 9
PMID 25567105
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridium difficile infection (CDI) is the leading cause of death due to gastrointestinal infections in the US and is the most common cause of nosocomial diarrhea. The emergence of a hypervirulent strain in the early 2000s has been associated with a dramatic increase in the number and severity of cases in the US, Canada, and several other countries. Most cases are related to antibiotic use, but sporadic cases occur in otherwise healthy individuals with no risk factors. Morbidity and mortality are highest in the elderly. Diagnosis is confirmed by detection of C. difficile toxin in the stools. Treatment should be stratified by severity of disease, with metronidazole use for mild disease cases and vancomycin for severe disease. Recurrent CDI occurs in 10-20 % of cases. A first recurrence can be treated with a ten-day regimen of metronidazole or vancomycin; a second recurrence is best treated by a pulsed regimen of vancomycin. In patients with multiple (three or more) recurrences, fecal microbiota transplant has a high rate of success. The most important methods of prevention are wise antibiotic policies, hand hygiene, isolation, and barrier methods in hospital and long-term care facilities (LCTF) settings.

Citing Articles

Predictors of Clostridium difficile infection after stoma reversal following TaTME surgery.

Tirelli F, Lorenzon L, Biondi A, Langellotti L, Santoro G, Agnes A Updates Surg. 2023; 75(6):1589-1596.

PMID: 37540407 PMC: 10435656. DOI: 10.1007/s13304-023-01614-4.


Burden of Infection among Patients in Western Asia: A Systematic Review and Meta-Analysis.

Malekzadegan Y, Halaji M, Hasannejad-Bibalan M, Jalalifar S, Fathi J, Ebrahim-Saraie H Iran J Public Health. 2019; 48(9):1589-1599.

PMID: 31700814 PMC: 6825664.


Impact of superimposed Clostridium difficile infection in Crohn's or ulcerative colitis flares in the outpatient setting.

Garcia P, Chebli L, Ribeiro T, Gaburri P, Pace F, Barbosa K Int J Colorectal Dis. 2018; 33(9):1285-1294.

PMID: 29926235 DOI: 10.1007/s00384-018-3105-8.


Using bugs as drugs: Microbial ecosystem therapeutics.

Allen-Vercoe E, Petrof E Can Commun Dis Rep. 2018; 45(Suppl 5):3-6.

PMID: 29770104 PMC: 5868539. DOI: 10.14745/ccdr.v41is5a01.


Risk factors for infections - an overview of the evidence base and challenges in data synthesis.

Eze P, Balsells E, Kyaw M, Nair H J Glob Health. 2017; 7(1):010417.

PMID: 28607673 PMC: 5460399. DOI: 10.7189/jogh.07.010417.


References
1.
Surawicz C, Brandt L, Binion D, Ananthakrishnan A, Curry S, Gilligan P . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-98. DOI: 10.1038/ajg.2013.4. View

2.
Lamontagne F, Labbe A, Haeck O, Lesur O, Lalancette M, Patino C . Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007; 245(2):267-72. PMC: 1876996. DOI: 10.1097/01.sla.0000236628.79550.e5. View

3.
Freedberg D, Salmasian H, Friedman C, Abrams J . Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013; 108(11):1794-801. PMC: 3966060. DOI: 10.1038/ajg.2013.333. View

4.
Petrof E, Gloor G, Vanner S, Weese S, Carter D, Daigneault M . Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome. 2014; 1(1):3. PMC: 3869191. DOI: 10.1186/2049-2618-1-3. View

5.
Slimings C, Riley T . Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2013; 69(4):881-91. DOI: 10.1093/jac/dkt477. View